Even with the use of a number of approved drugs (prostanoids, endothelin antagonists, and PDE5 inhibitors) for PAH (group 1 PH), mortality rates in these patients remain high at 14% at 1 year and 39% at 5 years [20], [21]. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.